II. Background

  1. Aspirin has historically been considered in all diabetic patients or starting at age 45 years in men and age 55 years in women
  2. However consider benefit of 7 years Aspirin (1 less CV event in 90) versus life threatening bleeding risk (1 in 110)
    1. (2018) Presc Lett 25(11): 61

III. Indications: Low dose Aspirin 81 mg daily (more specific as of 2012)

  1. Framingham risk >10%, no vascular disease, and no Bleeding Diathesis
  2. Males over age 50 years or females over age 60 years and
  3. One additional Cardiovascular Risk Factor
    1. Tobacco Abuse
    2. Hypertension
    3. Dyslipidemia
    4. Albuminuria
    5. Family History of premature cardiovascular death

IV. Indications: Clopidogrel (Plavix) 75 mg daily

  1. Known cardiovascular disease

V. Adverse Effects

  1. See Aspirin
  2. Aspirin does not increase risk of Retinal Hemorrhage

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Antiplatelet therapy (C1096021)

Concepts Therapeutic or Preventive Procedure (T061)
Italian Terapia antipiastrinica
Japanese 抗血小板療法, コウケッショウバンリョウホウ
Czech Antiagregační léčba
English antiplatelet therapy, Antiplatelet therapy
Hungarian Thrombocyta-gátló kezelés
Portuguese Tratamento anti-plaquetas
Spanish Tratamiento antiplaquetario
Dutch antibloedplaatjestherapie
French Traitement antiplaquettaire
German Therapie mit Thrombozytenaggregationshemmer